Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)
Open Access
Abstract
To determine whether once-daily esomeprazole 40 mg or 20 mg compared with placebo reduces the incidence of peptic ulcers over 26 weeks of treatment in patients taking low-dose acetylsalicylic acid (ASA) and who are at risk for ulcer development. Multinational, randomised, blinded, parallel-group, placebo-controlled trial. Cardiology, primary care and gastroenterology centres (n=240). Helicobacter pylori-negative patients taking daily low-dose ASA (75-325 mg), who fulfilled one or more of the following criteria: age ≥18 years with history of uncomplicated peptic ulcer; age ≥60 years with either stable coronary artery disease, upper gastrointestinal symptoms and five or more gastric/duodenal erosions, or low-dose ASA treatment initiated within 1 month of randomisation; or age ≥65 years. All patients were ulcer-free at study entry. Once-daily, blinded treatment with esomeprazole 40 mg, 20 mg or placebo for 26 weeks. The primary end point was the occurrence of endoscopy-confirmed peptic ulcer over 26 weeks. A total of 2426 patients (52% men; mean age 68 years) were randomised. After 26 weeks, esomeprazole 40 mg and 20 mg significantly reduced the cumulative proportion of patients developing peptic ulcers; 1.5% of esomeprazole 40 mg and 1.1% of esomeprazole 20 mg recipients, compared with 7.4% of placebo recipients, developed peptic ulcers (both p<0.0001 vs placebo). Esomeprazole was generally well tolerated. Conclusions Acid-suppressive treatment with once-daily esomeprazole 40 mg or 20 mg reduces the occurrence of peptic ulcers in patients at risk for ulcer development who are taking low-dose ASA. Clinical trial registration number ClinicalTrials.gov identifier: NCT00441727.Keywords
This publication has 33 references indexed in Scilit:
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2009
- Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low‐dose aspirin and nonsteroidal anti‐inflammatory drugsAlimentary Pharmacology & Therapeutics, 2008
- Cardioprotective aspirin users and their excess risk of upper gastrointestinal complicationsBMC Medicine, 2006
- Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinAlimentary Pharmacology & Therapeutics, 2005
- Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of CardiologyEuropean Heart Journal, 2004
- Risk of upper gastrointestinal bleeding in patients taking low‐dose aspirin for the prevention of cardiovascular diseasesAlimentary Pharmacology & Therapeutics, 2002
- AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 UpdateCirculation, 2002
- Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2002
- Risk of upper gastrointestinal bleeding associated with use of low-dose aspirinAmerican Journal of Gastroenterology, 2000